Hims & Hers
Editorial reviewMass-market, app-first weight program with nationwide reach and consumer-grade polish.
Visit Hims & HersHead-to-head verdict
Two GLP-1 providers, ruled side by side on The Verdict Score — our published six-factor rubric. Same yardstick, no pay-to-win placement.
Mass-market, app-first weight program with nationwide reach and consumer-grade polish.
Visit Hims & HersThe most honest middle of the market: nationwide access, both molecules at one flat, no-surprise price.
Visit CoreAge RxCoreAge Rx takes it with a higher Verdict Score — 94/100 to 85/100 (grade A vs B). Anyone who wants transparent flat pricing and nationwide access without a teaser-rate bait-and-switch. Hims & Hers still earns its place — people who want a familiar, app-driven consumer brand.
Both scored on the same six factors — see the methodology. The brass bar marks the stronger side on each.
| Metric | Hims & Hers | CoreAge Rx |
|---|---|---|
| Verdict Score | 85/100 | 94/100 |
| Grade | B | A |
| Semaglutide | $199/mo | $149/mo |
| Tirzepatide | Not disclosed | $349/mo |
| Coverage | All 50 states | All 50 states |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | No | No |
| Relationship | Editorial | Partner |
What we like
The caveats
What we like
The caveats
Also worth a look
People who want a familiar, app-driven consumer brand.
Visit Hims & Hers Read the full Hims & Hers review →Our pick — visit
Anyone who wants transparent flat pricing and nationwide access without a teaser-rate bait-and-switch.
Visit CoreAge Rx Read the full CoreAge Rx review →Or browse the full comparison hub and the complete rankings.
Pricing, states and verification reflect each provider's public disclosures at last review; the Verdict Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.